{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:02:06Z","timestamp":1784912526640,"version":"3.55.0"},"reference-count":93,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Hypertriglyceridemia (HTG) is a well-established independent cardiovascular risk factor. Severe (triglycerides [TGs] &amp;gt; 500\u2005mg\/dL) or extreme HTG (&amp;gt; 1000\u2005mg\/dL) that persist despite the correction of secondary causes are also associated with a markedly increased risk of recurrent acute pancreatitis and represent a substantial unmet medical need. Several novel therapies are progressively emerging and being incorporated into the treatment landscape for the management of severe HTG (sHTG) and associated risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence acquisition<\/jats:title>\n                    <jats:p>Naturally occurring loss-of-function variants in genes involved in TG metabolism have been identified; carriers of these variants tend to exhibit a favorable lipid profile and reduced cardiovascular risk. Therapeutic strategies have been developed to inhibit these genes or their corresponding proteins through diverse mechanisms of action. In addition, several other proteins and hormones influencing TG metabolism have been identified in the last decade and have emerged as promising targets for sHTG treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence synthesis<\/jats:title>\n                    <jats:p>This review summarizes novel therapeutic targets, mechanisms of action, and the ongoing clinical development of emerging treatments aimed at improving the management of TG-rich lipoproteins, reducing TG levels and mitigating associated risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sHTG remains an important unmet medical need. Considerable research efforts are currently focused on the development of innovative, effective, and safe therapeutic interventions aimed at reducing the risks associated with sHTG. At present, the use of most of these emerging therapies remains limited to selected patient populations, while broader indications continue to be investigated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag280","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:52:30Z","timestamp":1784807550000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of severe hypertriglyceridemia: a new era dawns"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2356-5396","authenticated-orcid":false,"given":"Miriam","family":"Larouche","sequence":"first","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 , Chicoutimi , G7H 7K9","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 , Chicoutimi , G7H 7K9","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"47","key":"2026072412142975900_dgag280-B1","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"42","key":"2026072412142975900_dgag280-B2","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"21","key":"2026072412142975900_dgag280-B3","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026072412142975900_dgag280-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101067","article-title":"Real-world prescribing in accordance to ACC\/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD: real-world prescribing for lipid-lowering therapy","volume":"23","author":"Arnold","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"19","key":"2026072412142975900_dgag280-B5","first-page":"2624","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Members","year":"2026","journal-title":"Circulation"},{"key":"2026072412142975900_dgag280-B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100978","article-title":"Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the national lipid association and the American society for preventive cardiology","volume":"22","author":"Saadatagah","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"4","key":"2026072412142975900_dgag280-B7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacl.2025.03.012","article-title":"Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the national lipid association and the American society for preventive Cardiology","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"7","key":"2026072412142975900_dgag280-B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11883-017-0667-9","article-title":"Genetics of triglycerides and the risk of atherosclerosis","volume":"19","author":"Dron","year":"2017","journal-title":"Curr Atheroscler Rep"},{"issue":"17","key":"2026072412142975900_dgag280-B9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia","volume":"376","author":"Beigneux","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026072412142975900_dgag280-B10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacl.2017.05.017","article-title":"GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia","volume":"11","author":"Hu","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"7","key":"2026072412142975900_dgag280-B11","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1210\/jc.2005-0205","article-title":"Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia","volume":"90","author":"Pruneta-Deloche","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026072412142975900_dgag280-B12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2026072412142975900_dgag280-B13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European atherosclerosis society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026072412142975900_dgag280-B14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"issue":"12","key":"2026072412142975900_dgag280-B15","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"2026072412142975900_dgag280-B16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the national lipid association","volume":"19","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026072412142975900_dgag280-B17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/B978-0-323-88286-6.00004-2","volume-title":"Clinical Lipidology","author":"Tybj\u00e6rg-Hansen","year":"2024","edition":"3rd ed"},{"issue":"12","key":"2026072412142975900_dgag280-B18","first-page":"1251","article-title":"Acute pancreatitis","volume":"82","author":"Szatmary","year":"2022","journal-title":"Diagnosis and Treatment. Drugs"},{"issue":"3","key":"2026072412142975900_dgag280-B19","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13916","article-title":"Mechanisms linking hypertriglyceridemia to acute pancreatitis","volume":"237","author":"Kiss","year":"2023","journal-title":"Acta Physiol (Oxf)"},{"issue":"8","key":"2026072412142975900_dgag280-B20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41575-019-0158-2","article-title":"New insights into acute pancreatitis","volume":"16","author":"Lee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"2026072412142975900_dgag280-B21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.126.327270","article-title":"New and emerging therapeutic targets for ApoB-containing particles lowering","volume":"138","author":"Gaudet","year":"2026","journal-title":"Circ Res"},{"issue":"18","key":"2026072412142975900_dgag280-B22","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"10","key":"2026072412142975900_dgag280-B23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"2026072412142975900_dgag280-B24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOL.0b013e328352dc70","article-title":"Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production","volume":"23","author":"Yao","year":"2012","journal-title":"Curr Opin Lipidol"},{"issue":"5908","key":"2026072412142975900_dgag280-B25","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"12","key":"2026072412142975900_dgag280-B26","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(14)61453-4","article-title":"An antisense inhibitor of apolipoprotein C-III significantly decreases apolipoprotein C-III, triglycerides, very-low-density lipoprotein cholesterol and particle number, and increases high-density lipoprotein cholesterol and particle number in hypertriglyceridemic patients on a fibrate","volume":"63","author":"Alexander","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2026072412142975900_dgag280-B27","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2026072412142975900_dgag280-B28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2026072412142975900_dgag280-B29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"6","key":"2026072412142975900_dgag280-B30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2026072412142975900_dgag280-B31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026072412142975900_dgag280-B32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"2026072412142975900_dgag280-B33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"key":"2026072412142975900_dgag280-B34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ahj.2025.02.022","article-title":"Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: rationale and design of the essence-TIMI 73b trial","volume":"286","author":"Bergmark","year":"2025","journal-title":"Am Heart J"},{"issue":"19","key":"2026072412142975900_dgag280-B35","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072412142975900_dgag280-B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09846-1","article-title":"Efficacy of olezarsen in severe hypertriglyceridemia and acute pancreatitis risk: a systematic review and meta-analysis of randomized controlled trials","author":"Rehman","year":"2026","journal-title":"Dig Dis Sci"},{"issue":"12","key":"2026072412142975900_dgag280-B37","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid"},{"issue":"7","key":"2026072412142975900_dgag280-B38","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2026072412142975900_dgag280-B39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026072412142975900_dgag280-B40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"2026072412142975900_dgag280-B41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK early access to medicines scheme (EAMS)","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"issue":"Suppl_3","key":"2026072412142975900_dgag280-B42","doi-asserted-by":"crossref","DOI":"10.1161\/circ.152.suppl_3.4361462","article-title":"Abstract 4361462: RN0361, an siRNA directed against ApoC3 demonstrates potent and durable reduction of ApoC3 and triglyceride over 6 months in the clinic","volume":"152","author":"DePaoli","year":"2025","journal-title":"Circulation"},{"issue":"Suppl_1","key":"2026072412142975900_dgag280-B43","article-title":"Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice","volume":"45","author":"Luo","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"2026072412142975900_dgag280-B44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"issue":"2","key":"2026072412142975900_dgag280-B45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MED.0000000000000857","article-title":"APOC3 siRNA and ASO therapy for dyslipidemia","volume":"31","author":"Chebli","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026072412142975900_dgag280-B46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2026.101523","article-title":"Use of plozasiran across a spectrum of hypertriglyceridemia: long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR trials","volume":"27","author":"Ballantyne","year":"2026","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"2026072412142975900_dgag280-B47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tem.2020.11.005","article-title":"Lipoprotein lipase and its regulators: an unfolding story","volume":"32","author":"Wu","year":"2021","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"2026072412142975900_dgag280-B48","article-title":"The regulation of triacylglycerol metabolism and lipoprotein lipase activity","volume":"6","author":"Wen","year":"2022","journal-title":"Adv Biol (Weinh)"},{"issue":"27","key":"2026072412142975900_dgag280-B49","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"2026072412142975900_dgag280-B50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"2026072412142975900_dgag280-B51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2026072412142975900_dgag280-B52","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2026072412142975900_dgag280-B53","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"issue":"9","key":"2026072412142975900_dgag280-B54","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2026072412142975900_dgag280-B55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026072412142975900_dgag280-B56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(25)00290-6","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial","volume":"14","author":"Raal","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"2026072412142975900_dgag280-B57","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2025.03.005","article-title":"Effect of ANGPTL3 inhibition with solbinsiran in preclinical and early human studies","volume":"85","author":"Ray Kausik","year":"2025","journal-title":"JACC"},{"issue":"10489","key":"2026072412142975900_dgag280-B58","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3):\u2008a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"The Lancet"},{"issue":"21","key":"2026072412142975900_dgag280-B59","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 trial of CRISPR-cas9 gene editing targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"2026072412142975900_dgag280-B60","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"19","key":"2026072412142975900_dgag280-B61","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCULATIONAHA.123.065866","article-title":"ANGPTL3 deficiency and risk of hepatic steatosis","volume":"148","author":"D'Erasmo","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"2026072412142975900_dgag280-B62","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"2026072412142975900_dgag280-B63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009501","article-title":"ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease","volume":"17","author":"Helkkula","year":"2021","journal-title":"PLoS Genet"},{"issue":"5","key":"2026072412142975900_dgag280-B64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100198","article-title":"An anti-ANGPTL3\/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif","volume":"63","author":"Balasubramaniam","year":"2022","journal-title":"J Lipid Res"},{"issue":"12","key":"2026072412142975900_dgag280-B65","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2026072412142975900_dgag280-B66","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2026072412142975900_dgag280-B67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ng1984","article-title":"Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL","volume":"39","author":"Romeo","year":"2007","journal-title":"Nat Genet"},{"issue":"10","key":"2026072412142975900_dgag280-B68","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1194\/jlr.M094128","article-title":"Characterization of ANGPTL4 function in macrophages and adipocytes using Angptl4-knockout and Angptl4-hypomorphic mice","volume":"60","author":"Oteng","year":"2019","journal-title":"J Lipid Res"},{"issue":"7","key":"2026072412142975900_dgag280-B69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100237","article-title":"ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy","volume":"63","author":"Deng","year":"2022","journal-title":"J Lipid Res"},{"issue":"10493","key":"2026072412142975900_dgag280-B70","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"The Lancet"},{"issue":"7","key":"2026072412142975900_dgag280-B71","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"2026072412142975900_dgag280-B72","article-title":"DR10624, a first-in-class FGF21 receptor\/glucagon receptor\/GLP-1 receptor triple agonist, rapidly and significantly reduced triglycerides, atherogenic lipid and liver fat in patients with severe hypertriglyceridaemia: primary results from a randomized phase 2 trial","author":"Li","year":"2025","journal-title":"Circulation"},{"issue":"10","key":"2026072412142975900_dgag280-B73","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1111\/dom.16661","article-title":"Decreases in circulating ANGPTL3\/8 concentrations following retatrutide treatment parallel reductions in serum lipids","volume":"27","author":"Wen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"10366","key":"2026072412142975900_dgag280-B74","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"2026072412142975900_dgag280-B75","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2026072412142975900_dgag280-B76","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2026072412142975900_dgag280-B77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","article-title":"Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"2026072412142975900_dgag280-B78","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/dme.12301","article-title":"The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits","volume":"30","author":"Ryder","year":"2013","journal-title":"Diabet Med"},{"issue":"6","key":"2026072412142975900_dgag280-B79","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2026072412142975900_dgag280-B80","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"2026072412142975900_dgag280-B81","doi-asserted-by":"crossref","first-page":"424","DOI":"10.14309\/ajg.0000000000003525","article-title":"Glucagon-like peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type 2 diabetes who develop acute pancreatitis: a multicenter analysis","volume":"121","author":"Nieto","year":"2026","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2026072412142975900_dgag280-B82","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.eprac.2026.02.014","article-title":"Clinical guidelines for the diagnosis and management of generalized and partial lipodystrophies: a position statement endorsed by the hellenic endocrine society","volume":"32","author":"Lambadiari","year":"2026","journal-title":"Endocr Pract"},{"issue":"528","key":"2026072412142975900_dgag280-B83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7905","article-title":"A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides","volume":"12","author":"Wolska","year":"2020","journal-title":"Sci Transl Med"},{"issue":"11","key":"2026072412142975900_dgag280-B84","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1194\/jlr.R120001116","article-title":"Chylomicronemia from GPIHBP1 autoantibodies","volume":"61","author":"Miyashita","year":"2020","journal-title":"J Lipid Res"},{"issue":"9","key":"2026072412142975900_dgag280-B85","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/L20-0327","article-title":"Chylomicronemia from GPIHBP1 autoantibodies successfully treated with rituximab: a case report","volume":"173","author":"Lutz","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026072412142975900_dgag280-B86","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jacl.2020.01.012","article-title":"Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies","volume":"14","author":"Ashraf","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"23","key":"2026072412142975900_dgag280-B87","article-title":"Successful rituximab treatment of GPIHBP1 autoantibody-associated hypertriglyceridemia","volume":"30","author":"Hussain","year":"2025","journal-title":"JACC Case Rep"},{"issue":"1","key":"2026072412142975900_dgag280-B88","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ando.2022.12.384","article-title":"R\u00e9mission d\u2019une hypertriglyc\u00e9rid\u00e9mie auto-immune s\u00e9v\u00e8re apr\u00e8s traitement immunosuppresseur","volume":"84","author":"Smati","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"17-18","key":"2026072412142975900_dgag280-B89","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1089\/hum.2023.075","article-title":"Preclinical development and characterization of novel adeno-associated viral vectors for the treatment of lipoprotein lipase deficiency","volume":"34","author":"Mehta","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2026072412142975900_dgag280-B90","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther"},{"issue":"4","key":"2026072412142975900_dgag280-B91","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","article-title":"Gene therapy for lipoprotein lipase deficiency","volume":"23","author":"Gaudet","year":"2012","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"2026072412142975900_dgag280-B92","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026072412142975900_dgag280-B93","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum Gene Ther"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag280\/69955557\/dgag280.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag280\/69955557\/dgag280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:14:43Z","timestamp":1784909683000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag280\/8741497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":93,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag280","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"dgag280"}}